Wave Life Sciences Ltd. (WVE)
Stock Price:
$9.39 USD
-0.04 (-0.42%)
Updated Aug 11, 2020 2:36 PM EDT - Market open
Key Info
| Market Cap |
335.53M |
| Revenue (ttm) |
17.12M |
| Net Income (ttm) |
-196.93M |
| Shares Out |
35.73M |
| EPS (ttm) |
-5.74 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 11, 2020 |
| Last Price |
$9.39 |
| Previous Close |
$9.43 |
| Change ($) |
-0.04 |
| Change (%) |
-0.42% |
| Day's Open |
9.50 |
| Day's Range |
9.26 - 9.50 |
| Day's Volume |
195,244 |
| 52-Week Range |
6.61 - 39.98 |
More Stats
| Market Cap |
335.53M |
| Enterprise Value |
246.36M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
35.73M |
| Float |
4.73M |
| EPS (basic) |
-5.74 |
| EPS (diluted) |
-5.74 |
| FCF / Share |
-4.88 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
5.20M |
| Short Ratio |
14.06 |
| Short % of Float |
20.47% |
| Beta |
-0.09 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
19.60 |
| PB Ratio |
15.38 |
| Revenue |
17.12M |
| Operating Income |
-210.32M |
| Net Income |
-196.93M |
| Free Cash Flow |
-168.09M |
| Net Cash |
89.17M |
| Net Cash / Share |
2.50 |
| Gross Margin |
-931.46% |
| Operating Margin |
-1,228.66% |
| Profit Margin |
-1,150.40% |
| FCF Margin |
-981.95% |
| ROA |
-38.65% |
| ROE |
-168.71% |
| ROIC |
-484.30% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (7)
| Buy |
4 |
| Overweight |
0 |
| Hold |
3 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$16.50*
(75.72% upside)
Low
8.00
Current: $9.39
High
21.00
Target: 16.50
*Average 12-month price target from 6 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|
| Revenue | 15.98 | 14.41 | 3.89 | 1.09 | 0.15 | - | - |
| Revenue Growth | 10.89% | 270.25% | 256.5% | 618.42% | - | - | - |
| Gross Profit | 15.98 | 14.41 | 3.89 | 1.09 | 0.15 | - | - |
| Operating Income | -208 | -160 | -102 | -55.72 | -19.30 | -5.39 | -3.57 |
| Net Income | -194 | -147 | -102 | -55.66 | -19.20 | -5.23 | -3.32 |
| Shares Outstanding | 33.87 | 28.97 | 26.51 | 22.80 | 10.50 | 3.91 | 1.74 |
| Earnings Per Share | -5.72 | -5.06 | -3.85 | -2.44 | -1.83 | -1.34 | -1.90 |
| Operating Cash Flow | -188 | -22.86 | -83.67 | -31.93 | -12.53 | -4.43 | -3.55 |
| Capital Expenditures | -3.92 | -9.94 | -18.89 | -5.56 | -1.86 | -0.58 | -0.05 |
| Free Cash Flow | -192 | -32.80 | -103 | -37.49 | -14.38 | -5.00 | -3.60 |
| Cash & Equivalents | 147 | 175 | 143 | 150 | 162 | 1.05 | 0.00 |
| Total Debt | 32.55 | - | 0.02 | 0.08 | 0.14 | - | - |
| Net Cash / Debt | 115 | 175 | 142 | 150 | 162 | 1.05 | 0.00 |
| Assets | 284 | 296 | 182 | 165 | 165 | 2.94 | - |
| Liabilities | 213 | 215 | 34.36 | 22.07 | 4.06 | 0.91 | - |
| Book Value | 63.73 | 73.35 | 140 | 135 | 153 | 2.03 | - |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Wave Life Sciences Ltd. |
| Country |
Singapore |
| Employees |
301 |
| CEO |
Paul B. Bolno |
Stock Information
| Ticker Symbol |
WVE |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: WVE |
| IPO Date |
November 11, 2015 |
Description
Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces of novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. The company is primarily developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins. It focuses on programs in neurology in the central nervous system and neuromuscular system. The company has a research, license, and option agreement with Pfizer Inc. and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of stereopure oligonucleotide therapeutics and oligonucleotide therapeutics; and research, development, and develop antisense oligonucleotides. Wave Life Sciences Ltd. was founded in 2012 and is based in Singapore.